ReviewTranslational gastroenterology and hepatology2025
Overlap syndromes in autoimmune liver disease: a review.
Review in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- RNA mActa pharmacologica Sinica · 2026Review
- Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Autoimmune Hepatitis/Primary Sclerosing Cholangitis Overlap Syndrome Associated With Minimal Change Disease and Tubulointerstitial Nephritis.ACG case reports journal · 2026Article
- Autoantibodies in the follow-up of autoimmune hepatitis.Journal of translational autoimmunity · 2026Review
- Beyond the Gut: Extra-Enteric Digestive Manifestations of Inflammatory Bowel Disease-A Personalized Medicine Perspective and Comprehensive Review.Journal of personalized medicine · 2026Review
- Use of Machine Learning in Predicting the Risk of Cirrhosis in Autoimmune Hepatitis Based on Clinical and Immunological Indicators.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical and Demographic Features of Primary Biliary Cholangitis in Kazakhstan.Diseases (Basel, Switzerland) · 2026Article
- "From Cholestasis to Interface Hepatitis: A Rare Case of Primary Sclerosing Cholangitis-Autoimmune Hepatitis Overlap in a 20-Year-Old Male".Clinical medicine insights. Case reports · 2026Article
- From Isolation to Information: Launching an Online Community for Patients with Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, and Autoimmune Hepatitis in Romania-A Descriptive Study.Healthcare (Basel, Switzerland) · 2025Article
- Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets.Journal of clinical medicine · 2025Review
- Profile of Patients with Primary Biliary Cholangitis and Evaluation of Response to Ursodeoxycholic Acid in a Romanian Center-Retrospective Study.Journal of clinical medicine · 2025Article
- The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine.Clinical reviews in allergy & immunology · 2025Review
- Article
- Human T-Lymphotropic Virus Type 1-Associated Myelopathy With Autoimmune Cholangiopathy: An Unusual Immune Conundrum in a Young Patient.Case reports in infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Self-directed immune-mediated injury to hepatocytes and cholangiocytes results in autoimmune liver disease (AILD). AILD comprises three distinct entities: autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) and each of these autoimmune conditions has distinct phenotypic, serological, radiologic and laboratory findings. AIH is characterized by injury to the hepatocytes while PBC and PSC occur due to injury to bile ducts. Although, these are considered rare diseases, it is important to note that some patients can present with features characteristic of more than one AILD, and these conditions are described as overlap syndromes (OS). Currently, there is lack of data regarding the epidemiology of OS. Majority of the data regarding the epidemiology of OS comes from single-center and small studies. The clinical features of OS are similar to the underlying AILD. There is also no consensus on how to manage patients with OS and the management is dependent on treating the underlying AILDs. Management of PBC involves use of ursodeoxycholic acid (UDCA), while management of AIH involves the use of steroids and immunosuppressants. In this article, we will review the current literature on various OS and their respective diagnostic criteria. This article will also discuss epidemiology, clinical features, prognosis as well as outcomes among patients with various OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.